Drugs / ECC4703
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05552274 | Aug 2022 → Oct 2023 | metabolic dysfunction-associated steatohepatitis | Eccogene | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07334080 | Jan → May 2026 overdue | metabolic dysfunction-associated steatohepatitis | Eccogene | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07505303 | Mar → Oct 2026 expected | obesity disorder | Eccogene | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07288138 | Dec 2025 → Sep 2027 expected | metabolic dysfunction-associated steatohepatitis | Eccogene | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECC4703 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05552274 ↗ |
| Action | Activate | “a THRβ Agonist (ECC4703)” NCT07288138 ↗ |
| Route | Oral | “ECC4703 will be administered as oral capsules during each dosing day.” NCT05552274 ↗ |